Has Irina Bancos, MD received payments from drug or device companies?

Yes. Drug and device makers reported $114,119 in general payments to Irina Bancos, MD across 103 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Irina Bancos, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Irina Bancos, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Irina Bancos, MD

Endocrinology, Diabetes & Metabolism · Rochester, MNNPI 1659552412

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $70,726 of the $114,119 with a category attached, or 62.0%. 11 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 28.3% of the total. Among endocrinology, diabetes & metabolism clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$114,119in general payments, 2019–2025

Across 103 payments — averaging $1107.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Neurocrine Biosciences, Inc.$32K
Corcept Therapeutics$18K
AstraZeneca$16K
Recordati_rare_diseases_inc.$12K
Novo Nordisk$11K
HRA Pharma RARE Diseases$10K
plus $15K from 5 others

$5,146,314in research payments, 2019–2025

Across 309 payments — averaging $16,655 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Esteve Pharmaceuticals LLC$3.7M
Ascendis Pharma Endocrinology Inc$730K
Neurocrine Biosciences, Inc.$486K
Recordati_rare_diseases_inc.$167K
Corcept Therapeutics$107K

What the payments were for

Consulting fees$70,72662%
Speaking & faculty fees$24,34821%
Travel & lodging$15,47914%
Food & beverage$3,0653%
Charitable contribution$5000%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Neurocrine Biosciences, Inc.	44	$32,281
Corcept Therapeutics	19	$17,904
AstraZeneca	15	$16,040
Recordati_rare_diseases_inc.	8	$11,675
Novo Nordisk	5	$11,074
HRA Pharma RARE Diseases	4	$10,369
Esteve Pharmaceuticals LLC	2	$8,785
Progenics Pharmaceuticals, Inc.	2	$2,186
Strongbridge US Inc.	1	$1,800
Astrazeneca UK Limited	1	$1,611
Xeris Pharmaceuticals, Inc.	2	$394

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Korlym$17,566
OSILODROSTAT$11,592
Lysodren$6,400
CRENESSITY$6,367
METOPIRONE$3,900
AZEDRA$2,091
RECORLEV$394

How this compares

$114,119 in reported general payments places this provider in the 90th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.

See all endocrinology, diabetes & metabolism providers in Minnesota →

Medicare billing

Part B allowed, 2024

$21,319

Medicare patients

114

Services billed

178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OmnitropeSomatropin	15	$11,120
Hydrocortisone	67	$3,752
Eplerenone	16	$2,420
Testosterone Cypionate	22	$871
Fludrocortisone Acetate	30	$771
Levothyroxine Sodium	53	$499
Prednisone	40	$435
Dexamethasone	51	$56
Dexamethasone Sodium Phosphate	19	$32

Paid to pharmacies, not to this prescriber.

Other endocrinology, diabetes & metabolism in Rochester

Marjorie Ann MalbasRochester$222K
Maria CastroRochester$63K
Marius StanRochester$59K
Matthew DrakeRochester$41K
Manpreet MundiRochester$39K
Yogish KudvaRochester$38K
Bart ClarkeRochester$36K
Robert RizzaRochester$30K
Adrian VellaRochester$26K
Michael JensenRochester$22K

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →